Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I6IB
|
||||
| Former ID |
DAP000736
|
||||
| Drug Name |
Tenoxicam
|
||||
| Synonyms |
Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antiinflammatory Agents
|
||||
| Company |
Roche Laboratories Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H11N3O4S2
|
||||
| CAS Number |
CAS 59804-37-4
|
||||
| PubChem Compound ID | |||||
| SuperDrug ATC ID |
M01AC02
|
||||
| SuperDrug CAS ID |
cas=059804374
|
||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [536034], [536149] | |
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| References | |||||
| Ref 527467 | Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res. 2005 Jan;30(1):39-46. | ||||
| Ref 527583 | In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci. 2005 Spring;35(2):137-43. | ||||
| Ref 550768 | Drug information of Tenoxicam, 2008. eduDrugs. | ||||
| Ref 536034 | A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain control. Anaesth Intensive Care. 2004 Dec;32(6):770-4. | ||||
| Ref 536149 | The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.